Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis
